Zhonghua Yu Fang Yi Xue Za Zhi. 2020 Dec 6;54(12):1315-1363. doi: 10.3760/cma.j.cn112150-20201110-01353.
Pneumococcal disease is a serious global public health problem and a leading cause of morbidity and mortality of children and adults in China. Antibiotics are commonly used to treat pneumococcal disease. However, antibiotic resistance to has become a severe problem around the world due to widespread antibiotic use. Immunoprophylaxis of pneumococcal disease with pneumococcal vaccines is therefore of great importance. In this article, we review the etiology, clinical presentation, epidemiology, and disease burden of pneumococcal disease and the vaccinology of pneumococcal vaccines. Our review is based on the Expert Consensus on Immunoprophylaxis of Pneumococcal Disease (2017 version), the Pneumococcal Vaccines WHO Position Paper (2019), and recent national and international scientific advances. This consensus article aims to provide public health and vaccination staff with appropriate evidence for pneumococcal vaccine use and to improve professional capacity for pneumococcal disease prevention and control.
肺炎球菌疾病是一个严重的全球公共卫生问题,也是中国儿童和成人发病和死亡的主要原因。抗生素常用于治疗肺炎球菌疾病。然而,由于抗生素的广泛使用,全球范围内对抗生素的耐药性已成为一个严重问题。因此,使用肺炎球菌疫苗对肺炎球菌疾病进行免疫预防至关重要。在本文中,我们综述了肺炎球菌疾病的病因、临床表现、流行病学、疾病负担以及肺炎球菌疫苗的疫苗学。我们的综述基于《肺炎球菌疾病免疫预防专家共识(2017年版)》、《世界卫生组织肺炎球菌疫苗立场文件(2019年)》以及近期国内外的科学进展。这篇共识文章旨在为公共卫生和疫苗接种工作人员提供使用肺炎球菌疫苗的适当依据,并提高肺炎球菌疾病预防和控制的专业能力。